CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV) is a health care company focused on the development of SCENESSE, its proprietary first-in-class drug, as a photoprotective in a range of UV and light related skin disorders. The stock was trading at a market price of $12.560 and has seen a daily price change of $0.06 and a percentage of 0.48%, as at August 21, 2018, market open. The stock has seen a performance change of 90% over the past 12 months. Compared to the June quarter last year there has been a 66% increase in cash receipts from customers for the June 2018 quarter, at $10,388,000. The combination of cash receipts and expenditures contributed to a net operating activity for the quarter ended 30 June 2018, with positive cash flow of $7,440,000.
BIONOMICS LIMITED (ASX: BNO) is a health care company that saw its stock trading at a market price of $0.495 and has seen a daily price change of $0.045 and a percentage of 10% (August 21, 2018, market open). The stock has seen a performance change of 2.27% over the past 12 months. It is now executing on other ion channel discovery programs within its core areas of expertise of cognition, depression, PTSD and pain, to further demonstrate its skills in drug discovery. As per the preliminary 2017/2018 results, the group’s revenue and other income is down by 56% while loss from ordinary activities after tax has jumped up by 258% owing to investment in R&D (including trials related to BNC210) and lack of licensing income as seen last year.
CYNATA THERAPEUTICS LIMITED (ASX:CYP) is a regenerative stem cell and medicine development company whose stock was trading at a market price of $1.250 and has seen a daily price change of $0.015 and a percentage of 1.215% on August 20, 2018. The stock has seen a performance change of 133.64% over the past 12 months. Its study of Cymerus mesenchymal stem cells (MSCs) in a preclinical heart attack model enabled Cynata Therapeutics Limited to announce for positive efficacy. The study results add to Cynata’s growing number of successful analysis.
TELIX PHARMACEUTICALS LIMITED (ASX: TLX) is into commercializing and development of molecularly targeted radiation-based products for the treatment of cancer. The official listing year has been 2017 and the company is based in Flemington Road, North Melbourne, Australia. The stock was trading at a current market price of $0.800 and has seen a daily price change of $0.010 and a percentage of 1.266% on August 20, 2018. The stock has seen a performance change of 3.90% since listing of the stock. In collaboration with Nihon Medi-Physics, Telix is set to enter the Japanese Market for Renal cancer imaging.
BOTANIX PHARMACEUTICALS LTD (ASX: BOT) is a pharmaceuticals company whose stock was trading at a market price of $0.100 and has initially seen a price change of $0.005 and a percentage of 5% (August 21, 2018, market open) before reflecting flat trading. The stock has seen a performance change of 100.00% over the past one year. With advanced clinical programs and an exciting pipeline, Botanix is an emerging global dermatology company.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.